JPWO2020079692A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020079692A5 JPWO2020079692A5 JP2021519139A JP2021519139A JPWO2020079692A5 JP WO2020079692 A5 JPWO2020079692 A5 JP WO2020079692A5 JP 2021519139 A JP2021519139 A JP 2021519139A JP 2021519139 A JP2021519139 A JP 2021519139A JP WO2020079692 A5 JPWO2020079692 A5 JP WO2020079692A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- peptide
- composition according
- chemotherapy
- combination therapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 238000002512 chemotherapy Methods 0.000 claims 5
- 238000002648 combination therapy Methods 0.000 claims 5
- 238000011282 treatment Methods 0.000 claims 5
- 229960004768 irinotecan Drugs 0.000 claims 3
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 3
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims 2
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 2
- 229960002949 fluorouracil Drugs 0.000 claims 2
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims 2
- 235000008191 folinic acid Nutrition 0.000 claims 2
- 239000011672 folinic acid Substances 0.000 claims 2
- 229960001691 leucovorin Drugs 0.000 claims 2
- 230000001394 metastastic effect Effects 0.000 claims 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims 2
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims 2
- 238000009097 single-agent therapy Methods 0.000 claims 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 1
- 230000000202 analgesic effect Effects 0.000 claims 1
- 230000001387 anti-histamine Effects 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- KLEAIHJJLUAXIQ-JDRGBKBRSA-N irinotecan hydrochloride hydrate Chemical compound O.O.O.Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 KLEAIHJJLUAXIQ-JDRGBKBRSA-N 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229940048191 onivyde Drugs 0.000 claims 1
- 229960002621 pembrolizumab Drugs 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024137500A JP2024161518A (ja) | 2018-10-17 | 2024-08-19 | 転移性膵臓腺癌の処置 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862746587P | 2018-10-17 | 2018-10-17 | |
| US62/746,587 | 2018-10-17 | ||
| PCT/IL2019/051129 WO2020079692A1 (en) | 2018-10-17 | 2019-10-17 | Treatment of metastatic pancreatic adenocarcinoma |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024137500A Division JP2024161518A (ja) | 2018-10-17 | 2024-08-19 | 転移性膵臓腺癌の処置 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022504468A JP2022504468A (ja) | 2022-01-13 |
| JP2022504468A5 JP2022504468A5 (https=) | 2022-10-12 |
| JPWO2020079692A5 true JPWO2020079692A5 (https=) | 2022-10-12 |
| JP7542529B2 JP7542529B2 (ja) | 2024-08-30 |
Family
ID=68426576
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021519139A Active JP7542529B2 (ja) | 2018-10-17 | 2019-10-17 | 転移性膵臓腺癌の処置 |
| JP2024137500A Pending JP2024161518A (ja) | 2018-10-17 | 2024-08-19 | 転移性膵臓腺癌の処置 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024137500A Pending JP2024161518A (ja) | 2018-10-17 | 2024-08-19 | 転移性膵臓腺癌の処置 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12291570B2 (https=) |
| EP (1) | EP3866812A1 (https=) |
| JP (2) | JP7542529B2 (https=) |
| KR (1) | KR20210095139A (https=) |
| CN (3) | CN118403142A (https=) |
| AU (2) | AU2019360044B2 (https=) |
| BR (1) | BR112021007318A2 (https=) |
| CA (1) | CA3115802A1 (https=) |
| IL (2) | IL308722B2 (https=) |
| MX (1) | MX2021004291A (https=) |
| WO (1) | WO2020079692A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL274572B2 (en) | 2015-07-16 | 2024-01-01 | Biolinerx Ltd | Compositions and methods for treating cancer |
| WO2020079692A1 (en) | 2018-10-17 | 2020-04-23 | Biolinerx Ltd. | Treatment of metastatic pancreatic adenocarcinoma |
| WO2025032571A1 (en) * | 2023-08-07 | 2025-02-13 | Biolinerx Ltd. | Unit dosage forms and methods comprising bl8040 for intravenous administration |
| WO2025224720A1 (en) | 2024-04-24 | 2025-10-30 | Biolinerx Ltd. | Methods of selecting treatment regimen against solid tumors |
| SE2430349A1 (en) * | 2024-06-27 | 2025-12-28 | Linda Bojmar | Liver tissue-based methods for predicting cancer recurrence and tailoring treatment approaches |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4036945A (en) | 1976-05-03 | 1977-07-19 | The Massachusetts General Hospital | Composition and method for determining the size and location of myocardial infarcts |
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| ATE300615T1 (de) | 1990-08-29 | 2005-08-15 | Genpharm Int | Transgene mäuse fähig zur produktion heterologer antikörper |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5239078A (en) | 1990-11-21 | 1993-08-24 | Glycomed Incorporated | Matrix metalloprotease inhibitors |
| US5189178A (en) | 1990-11-21 | 1993-02-23 | Galardy Richard E | Matrix metalloprotease inhibitors |
| EP1210428B1 (en) | 1999-08-23 | 2015-03-18 | Dana-Farber Cancer Institute, Inc. | Pd-1, a receptor for b7-4, and uses therefor |
| JP4808363B2 (ja) | 2000-09-05 | 2011-11-02 | バイオカイン セラピューティックス リミテッド | 新規ポリペプチド及びこれを含む抗ｈｉｖ剤 |
| AR036993A1 (es) | 2001-04-02 | 2004-10-20 | Wyeth Corp | Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas |
| ES2350687T3 (es) | 2002-07-03 | 2011-01-26 | Ono Pharmaceutical Co., Ltd. | Composiciones de inmunopotenciación. |
| WO2004020462A1 (ja) | 2002-08-27 | 2004-03-11 | Fujii, Nobutaka | Ｃｘｃｒ４拮抗薬およびその用途 |
| CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| CN103555733A (zh) | 2005-01-05 | 2014-02-05 | F-星生物技术研究与开发有限公司 | 分子中互补决定区以外的区域中工程改造了的具有结合特性的合成免疫球蛋白结构域 |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| AT503902B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von immunglobulinen |
| CA2673719C (en) | 2006-12-21 | 2018-07-24 | Biokine Therapeutics Ltd. | T-140 peptide analogs having cxcr4 super-agonist activity for bone marrow recovery |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| WO2010098788A2 (en) | 2008-08-25 | 2010-09-02 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| CN102203132A (zh) | 2008-08-25 | 2011-09-28 | 安普利穆尼股份有限公司 | Pd-1拮抗剂的组合物和使用方法 |
| KR101814408B1 (ko) | 2008-09-26 | 2018-01-04 | 다나-파버 캔서 인스티튜트 인크. | 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도 |
| CA2744449C (en) | 2008-11-28 | 2019-01-29 | Emory University | Methods for the treatment of infections and tumors |
| WO2010089411A2 (en) | 2009-02-09 | 2010-08-12 | Universite De La Mediterranee | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| CN103932972A (zh) | 2009-03-30 | 2014-07-23 | 天蓝制药公司 | 聚合物-药剂缀合物、颗粒、组合物和相关使用方法 |
| US20110160159A1 (en) | 2009-09-15 | 2011-06-30 | John Ryan | Treatment of cancer |
| CA3083324A1 (en) | 2010-03-05 | 2011-09-09 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
| JP2013532153A (ja) | 2010-06-18 | 2013-08-15 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | 慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体 |
| JP6238459B2 (ja) | 2011-08-01 | 2017-11-29 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合アンタゴニストとｍｅｋ阻害剤を使用する癌の治療方法 |
| US9439942B2 (en) | 2012-04-24 | 2016-09-13 | Biokine Therapeutics Ltd. | Peptides and use thereof in the treatment of large cell lung cancer |
| AU2013202947B2 (en) * | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
| ES2812208T3 (es) | 2013-03-14 | 2021-03-16 | Bristol Myers Squibb Co | Combinación de un agonista de DR5 y un antagonista de anti-PD-1 y métodos de uso |
| EP3307778A1 (en) | 2015-06-12 | 2018-04-18 | Bristol-Myers Squibb Company | Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways |
| IL274572B2 (en) | 2015-07-16 | 2024-01-01 | Biolinerx Ltd | Compositions and methods for treating cancer |
| MX385425B (es) * | 2015-08-21 | 2025-03-18 | Ipsen Biopharm Ltd | Irinotecán liposomal y oxaliplatino, 5-fluoroacilo y leucovorina para usarse en el tratamiento de cáncer pancreático metastásico. |
| EP3535026A1 (en) | 2016-11-02 | 2019-09-11 | Ipsen Biopharm Limited | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin) |
| AU2018292618A1 (en) | 2017-06-27 | 2019-12-19 | Novartis Ag | Dosage regimens for anti-TIM-3 antibodies and uses thereof |
| WO2020079692A1 (en) | 2018-10-17 | 2020-04-23 | Biolinerx Ltd. | Treatment of metastatic pancreatic adenocarcinoma |
| WO2020148745A1 (en) | 2019-01-17 | 2020-07-23 | Biolinerx Ltd. | Specific combination therapy for treatment of pancreatic cancer |
| WO2020148744A1 (en) | 2019-01-17 | 2020-07-23 | Biolinerx Ltd. | Combination therapy for treatment of pancreatic cancer |
| WO2021009761A1 (en) | 2019-07-18 | 2021-01-21 | Biolinerx Ltd. | Combination therapy for the treatment of cancer |
| US11599666B2 (en) | 2020-05-27 | 2023-03-07 | Sap Se | Smart document migration and entity detection |
| JP2024501709A (ja) | 2020-12-30 | 2024-01-15 | バイオラインアールエックス・リミテッド | Ｂｌ－８０４０の組成物 |
-
2019
- 2019-10-17 WO PCT/IL2019/051129 patent/WO2020079692A1/en not_active Ceased
- 2019-10-17 CN CN202410450708.0A patent/CN118403142A/zh active Pending
- 2019-10-17 MX MX2021004291A patent/MX2021004291A/es unknown
- 2019-10-17 CN CN201980081755.XA patent/CN113164600A/zh active Pending
- 2019-10-17 AU AU2019360044A patent/AU2019360044B2/en active Active
- 2019-10-17 CN CN202410450735.8A patent/CN118356479A/zh active Pending
- 2019-10-17 BR BR112021007318-3A patent/BR112021007318A2/pt unknown
- 2019-10-17 JP JP2021519139A patent/JP7542529B2/ja active Active
- 2019-10-17 US US17/285,511 patent/US12291570B2/en active Active
- 2019-10-17 EP EP19797831.5A patent/EP3866812A1/en active Pending
- 2019-10-17 CA CA3115802A patent/CA3115802A1/en active Pending
- 2019-10-17 KR KR1020217014596A patent/KR20210095139A/ko not_active Ceased
- 2019-10-17 IL IL308722A patent/IL308722B2/en unknown
- 2019-10-17 IL IL282317A patent/IL282317B2/en unknown
-
2023
- 2023-02-14 US US18/109,281 patent/US20230242644A1/en active Pending
-
2024
- 2024-08-19 JP JP2024137500A patent/JP2024161518A/ja active Pending
-
2025
- 2025-02-17 AU AU2025201098A patent/AU2025201098A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023041862A5 (https=) | ||
| FI3849534T3 (fi) | Yhdistelmähoidot | |
| RU2008142899A (ru) | Композиции далбаванцина для лечения бактериальных инфекций | |
| JP2018528185A5 (https=) | ||
| RU2747124C2 (ru) | Способы лечения метастатического рака поджелудочной железы с помощью комбинированной терапии, включающей применение иринотекана и оксалиплатина | |
| NO20014842L (no) | Docetaksel i kombinasjon med rhuMAb HER2 for behandling av kreft | |
| JP2006513184A5 (https=) | ||
| IL300151A (en) | Combinations for cancer treatment | |
| JP2018514510A5 (https=) | ||
| EP1201247B1 (en) | Treatment of metastatic renal cell carcinoma | |
| WO2005011579A3 (en) | Treatment of dependence withdrawal | |
| JPWO2020250915A5 (https=) | ||
| Mornex et al. | Gemcitabine and radiation therapy in non-small cell lung cancer: state of the art | |
| JPWO2020079692A5 (https=) | ||
| JP2021522246A5 (https=) | ||
| Agrawal et al. | GEM 231, a second-generation antisense agent complementary to protein kinase A RIα subunit, potentiates antitumor activity of irinotecan in human colon, pancreas, prostate and lung cancer xenografts | |
| JP2022035920A5 (https=) | ||
| Schmoll | Development of treatment for advanced colorectal cancer: infusional 5-FU and the role of new agents | |
| JPWO2022240688A5 (https=) | ||
| JPWO2020112765A5 (https=) | ||
| EP2498606A1 (en) | Tivozanib and temsirolimus in combination | |
| Di Paola et al. | The EORTC soft tissue and bone sarcoma group | |
| Choy et al. | Irinotecan in combined-modality therapy for locally advanced non-small-cell lung cancer | |
| JP2012025734A (ja) | 骨髄異形性症候群を治療するための組成物および方法 | |
| TW202539722A (zh) | 治療癌症的組合物和方法 |